{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:53:41Z","timestamp":1777100021331,"version":"3.51.4"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T00:00:00Z","timestamp":1723334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Head &amp; Neck"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Induction chemotherapy of docetaxel plus cisplatin (TP) is myelosuppressive, leading to severe neutropenia and febrile neutropenia (FN). Herein, we aimed to investigate the efficacy and safety of mecapegfilgrastim in the prevention of neutropenia in patients with locally advanced nasopharyngeal carcinoma who received the TP regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 30 treatment\u2010naive patients with locally advanced nasopharyngeal carcinoma were included in this study. Mecapegfilgrastim 6\u2009mg was injected 24\u201348\u2009h after the completion of induction chemotherapy with the TP regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The incidence of grade \u22653 neutropenia during the three induction chemotherapy cycles was 6.7% (95% CI, 0.8%\u201322.1%). In the first cycle of chemotherapy, the incidence of grade \u22653 neutropenia was 3.3% (95% CI, 0.1%\u201317.2%). No FN or antibiotic usage was reported. All 30 patients completed the induction chemotherapy cycles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Mecapegfilgrastim effectively reduced the incidence of chemotherapy\u2010induced neutropenia and FN in patients with locally advanced nasopharyngeal carcinoma.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hed.27897","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T05:13:45Z","timestamp":1723439625000},"page":"263-268","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mecapegfilgrastim for the prophylaxis of chemotherapy\u2010induced neutropenia in locally advanced nasopharyngeal carcinoma: A prospective phase <scp>II<\/scp> clinical study"],"prefix":"10.1002","volume":"47","author":[{"given":"Qifeng","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Head and Neck Radiation Oncology Zhejiang Cancer Hospital  Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghong","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Radiation Oncology Zhejiang Cancer Hospital  Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Radiation Oncology Zhejiang Cancer Hospital  Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Radiation Oncology Zhejiang Cancer Hospital  Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changjuan","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Radiation Oncology Zhejiang Cancer Hospital  Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Radiation Oncology Zhejiang Cancer Hospital  Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weifeng","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Radiation Oncology Zhejiang Cancer Hospital  Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6877-9042","authenticated-orcid":false,"given":"Xiaozhong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Radiation Oncology Zhejiang Cancer Hospital  Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,8,11]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0031"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.081"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905287"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30410-7"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1545"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103244"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.07.95"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2015.12.002"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw325"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13565"},{"issue":"3","key":"e_1_2_11_12_1","first-page":"279","article-title":"Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma","volume":"28","author":"Xie F\u2010Y","year":"2009","journal-title":"Ai Zheng"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181d409f9"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg019"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.3.727"},{"issue":"7","key":"e_1_2_11_16_1","first-page":"638","article-title":"Chinese Society of Clinical Oncology (CSCO) guidelines for standardizad management of tumor chemoradiotherapy\u2010related neutropenia (version 2021)","volume":"26","author":"Qin S","year":"2021","journal-title":"Chin Clin Oncol"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1310"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70320-5"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/61913"}],"container-title":["Head &amp; Neck"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.27897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T11:00:28Z","timestamp":1734001228000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hed.27897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,11]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/hed.27897"],"URL":"https:\/\/doi.org\/10.1002\/hed.27897","archive":["Portico"],"relation":{},"ISSN":["1043-3074","1097-0347"],"issn-type":[{"value":"1043-3074","type":"print"},{"value":"1097-0347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,11]]},"assertion":[{"value":"2024-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}